Rifampin has been shown to impair both humoral and cell-mediated immune responses in animal models. In order to detect a similar effect in man, 11 patients with active tuberculosis were evaluated before, 2 weeks after, and 12 to 16 weeks after initiating rifampin. Several parameters were serially measured including blood lymphocytes, intradermal response to intermediate strength tuberculin (PPD), and in vitro proliferative responses to phytohemagglutinin (PHA), a nonspecific mitogen, and to the specific antigens, PPD and influenza A. No changes in lymphocyte counts were noted. No changes in response were noted 2 weeks after beginning treatment with rifampin. However, compared with initial and 2-week responses, the PHA response was reduced by 47%, the PPD by 68%, and the influenza by 75%, and 6 of 11 patients showed no induration after tuberculin skin testing at the 12-to 16-week point. These results indicate that in doses employed for the treatment of tuberculosis, rifampin has an immunosuppressive effect in man that develops gradually.
Rifampin is currently recognized as one of the most effective new agents for tuberculosis therapy (8, 13) . In addition to its antibacterial properties, rifampin appears to have immunosuppressive activity. Paunescu (10) and others (3), using animal models, found that rifampin impairs antibody responses and skin test reactivity to several antigens. This effect is dose related and promptly reverses when the drug is discontinued. Rabbits treated with this agent show prolonged survival of skin grafts (12) .
In vitro studies demonstrate that rifampin reduces the proliferative responses of human lymphocytes to both tuberculin (PPD) and phytohemagglutinin (PHA) (2, 9) in a dosedependent manner. Rifampin cream applied to smallpox vaccination sites impairs production of antivaccinia hemagglutination-inhibiting antibody (6) . In patients receiving rifampin orally, humoral antibody responses to keyhole limpet hemocyanin are decreased (4) .
In the present study parameters of immune function in tuberculosis patients treated with rifampin were sequentially measured. Prolonged therapy was associated with decreased skin test reactivity to PPD and suppression of in vitro lymphoproliferative responses to both specific antigens and a nonspecific mitogen, PHA.
MATERIALS AND METHODS
Patients. Eleven adults of both sexes, aged 23 to 68 years (average 48 years) with active pulmonary tuberculosis, who were either hospitalized or being managed in the County Tuberculosis Clinic, were studied. Prior to initiating rifampin therapy, all patients were receiving two or more antituberculous drugs including isoniazid, streptomycin, and ethambutol. They had been treated with these antituberculosis drugs for periods ranging from days to several months. No patients had other major underlying diseases, and none was receiving corticosteroids or cytotoxic agents.
Rifampin dosage. Following the initial immunologic survey, treatment of all patients with 600 mg of rifampin in a single, daily morning dose was begun. Other antituberculosis drugs were continued throughout the study period.
Blood specimens. Blood was collected from each patient at three specific time intervals: before, 2 to 3 weeks after, and 12 to 16 weeks after initiation of rifampin therapy. Blood samples were obtained approximately 2 h after the patient had received his daily medication; serum was stored at -20 C. For lymphocyte studies, 30 to 50 ml of blood was collected in heparin (0.25 mg of a 1% heparin solution per 5 ml of blood) and handled as indicated below.
Vaccine studies. Patients received 0.5 ml of a 1972-73 formula, bivalent, influenza vaccine containing 700 CCA A/Aichi/68 and 300 CCA B/Mass/71 viruses. Hemagglutination-inhibiting (HAI) antibodies to influenza A/Aichi were measured as previously described (11) .
RUBEN, WINKELSTEIN, AND FOTIADIS
Lymphocyte cultures. Samples of heparinized blood were processed within 2 h of collection by using assay techniques reported in detail elsewhere (15) . Peripheral blood mononuclear cells were separated by the Ficoll-Hypaque method. Each culture contained 3.0 x 106 cells; antigen-stimulated cultures contained either PPD (20 ug/culture), PHA (0.1 ml/ culture), or influenza A antigen (0.1 ml of a suspension containing 800 hemagglutinating units of inactivated influenza A/Aichi/68 virus, the vaccine strain). Antigen-stimulated and control cultures were incubated for 5 days; the cultures containing PHA and unstimulated controls were incubated for 3 days.
At each time point, at least three cultures were incubated with antigen, and two or three unstimulated cultures served as controls.
Four hours prior to termination of the incubation, 1 Peripheral blood lymphocyte count. Pretreatment, 2-week, and 12-to 16-week blood lymphocyte counts were not significantly different (Fig. 1) . The values at these three times were 2,064/mms i 772, 2,432 i 511, and 2,136 i 417, respectively. Lymphocyte cultures. In each patient, lymphoproliferative responses to the nonspecific mitogen, PHA, and two specific antigens were measured at the three time periods. There was no significant change in the response to PHA at 2 weeks. However, after 12 to 16 weeks, the mean isotope uptake was reduced by 47% (Fig.  2) .
Responses to PPD are expressed as a stimulation ratio (Fig. 3) stimulated lymphocytes in the pretreatment specimen (7.9 i 1.1) was not significantly different from that at 2 weeks (7.0 0.9). However, at 12 to 16 weeks, the ratios were significantly lower (mean 2.5 0.8). It should be noted that the activity in the unstimulated control cultures was not altered at any time; thus, reduction in stimulation ratios represented a true depression of antigen-induced cell replication.
Similar responses were observed in influenzastimulated cultures (Fig. 4) . The average stimulation ratios in the pretreatment and 2-week samples ( Studies in nontuberculosis subjects. To test the effect of rifampin on the in vitro responses of lymphocytes to PHA, cultures were established from six normal subjects. At doses in excess of 10 gg/ml, rifampin impaired proliferative responses (Fig. 6) . Lesser As shown by these and other studies, rifampin, when added to lymphocyte cultures, can inhibit proliferative responses to PHA (2, 9) . It should be noted that such inhibition is not observed until the in vitro concentration exceeds 10 pg/ml, an amount greater than the usual blood levels (14) .
These results indicate that prolonged therapy with rifampin in humans exerts an immunosuppressive effect and are in accord with previously reported studies in animals (3, 10, 12 Although rifampin exerted a demonstrable immunosuppressive effect, all patients showed favorable responses to therapy. Acid-fast bacilli were eliminated from the sputum of all patients, and all are currently being treated as outpatients.
